Business Description
Cantargia AB
ISIN : SE0006371126
Compare
Compare
Traded in other countries / regions
CANTA.Sweden7V3.GermanyCANTAs.UK IPO Date
2018-07-20Description
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.62 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -1.4 | |||||
| 3-Year FCF Growth Rate | -3.1 | |||||
| 3-Year Book Growth Rate | -50.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.15 | |||||
| 9-Day RSI | 45.35 | |||||
| 14-Day RSI | 43.62 | |||||
| 6-1 Month Momentum % | -64.84 | |||||
| 12-1 Month Momentum % | -56.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.41 | |||||
| Quick Ratio | 2.41 | |||||
| Cash Ratio | 2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -154.72 | |||||
| ROA % | -115.89 | |||||
| ROIC % | -587.32 | |||||
| ROC (Joel Greenblatt) % | -4590.14 | |||||
| ROCE % | -154.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.45 | |||||
| Price-to-Tangible-Book | 6.97 | |||||
| EV-to-EBIT | -1.32 | |||||
| EV-to-Forward-EBIT | -0.38 | |||||
| EV-to-EBITDA | -1.35 | |||||
| EV-to-Forward-EBITDA | -1.14 | |||||
| EV-to-FCF | -1.32 | |||||
| Price-to-Net-Current-Asset-Value | 6.97 | |||||
| Price-to-Net-Cash | 13.93 | |||||
| Earnings Yield (Greenblatt) % | -75.76 | |||||
| FCF Yield % | -61.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cantargia AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.095 | ||
| Beta | 2.58 | ||
| Volatility % | 73.62 | ||
| 14-Day RSI | 43.62 | ||
| 14-Day ATR (€) | 0.008367 | ||
| 20-Day SMA (€) | 0.133 | ||
| 12-1 Month Momentum % | -56.77 | ||
| 52-Week Range (€) | 0.1251 - 0.4594 | ||
| Shares Outstanding (Mil) | 248.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cantargia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cantargia AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cantargia AB Frequently Asked Questions
What is Cantargia AB(FRA:7V3)'s stock price today?
The current price of FRA:7V3 is €0.14. The 52 week high of FRA:7V3 is €0.46 and 52 week low is €0.13.
When is next earnings date of Cantargia AB(FRA:7V3)?
The next earnings date of Cantargia AB(FRA:7V3) is 2025-02-21.
Does Cantargia AB(FRA:7V3) pay dividends? If so, how much?
Cantargia AB(FRA:7V3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers